The Society of Memorial Sloan Kettering Cancer Center

Share
Dr. Giralt is Deputy Head of the Division of Hematologic Malignancies

Sergio Giralt, MD, is Deputy Head of the Division of Hematologic Malignancies and holds the Melvin Berlin Family Chair in Multiple Myeloma.

The Society's longtime support has allowed MSK to pursue promising ideas to improve detection, diagnosis, and treatment of some of the most challenging cancers in the world. We are deeply grateful for this generous and visionary philanthropic partnership.
Lisa M. DeAngelis Physician-in-Chief, Chief Medical Officer, and Scott M. and Lisa G. Stuart Chair

The Society of Memorial Sloan Kettering Cancer Center (MSK) has forged a long tradition of fueling progress at MSK. Funds raised by dedicated volunteers of The Society have been essential to MSK’s continued innovation and advances in cancer care, research, and education for more than 75 years.

In 2022, The Society returned to hosting its in-person events. The Winter Lunch supported the Adolescent and Young Adult Fertility Preservation Fund at MSK, and in May, The Society celebrated its 15th annual Spring Ball. In attendance was Scott Stuart, Chair of MSK’s Board of Trustees, along with Craig B. Thompson, MD, who was honored for 12 years of leadership ahead of stepping down as MSK President and CEO in September. The Society hosted its first-ever Fall Lunch in October, gifts from which were allocated to the MSK Cancer Health Equity Research and Care Initiative, led by Carol Brown, MD, FACOG, FACS, Senior Vice President, Chief Health Equity Officer, and Nicholls-Biondi Chair for Health Equity.

The Society’s 2022–2023 campaign supported three key efforts in immunotherapy research:

  • Marcel van den Brink, MD, PhD

    Marcel van den Brink, MD, PhD, treats and researches blood malignancies.

    The work of hematologic oncologist Sergio Giralt, MD, to improve access and outcomes for patients who could benefit from chimeric antigen receptor (CAR) T cell therapy. Dr. Giralt is Deputy Head of the Division of Hematologic Malignancies and holds the Melvin Berlin Family Chair in Multiple Myeloma.
  • The investigations of stem cell transplant oncologist Marcel van den Brink, MD, PhD, into gut bacteria’s potential influence on the outcome of immune-based cancer treatments. Dr. van den Brink is Head of the Division of Hematologic Malignancies and holds the Alan N. Houghton Chair.
  • The Cell Therapy Correlative Core at MSK, a new hub to support immunotherapy efforts at all stages.
Muffie Potter Aston, President of The Society of MSK

Muffie Potter Aston is President of The Society of MSK.

Muffie Potter Aston assumed the role of The Society’s President in May 2022, following three years of distinguished service by Kate Allen. Muffie has been a member of The Society’s Administrative Board since 1999, served as Chair for many of its committees and events, and was Vice Chair of The Society’s Associates Committee. She will continue to build on The Society’s steadfast commitment to strengthening the impact of scientific and clinical leadership at MSK.

 

MSK 2022 Annual Report
It takes the people of MSK — in every operating room, every lab, every corridor, and every neighborhood — to achieve our mission: Ending cancer for life.
Learn more